EATG » Hepatitis

Hepatitis

Hepatitis C-infected organs deemed safe for transplant

SAN FRANCISCO — Direct-acting antiviral medications can make the transplantation of organs infected with hepatitis C safe for recipients who do not have the virus, new research shows. This finding…

DAA treatment and hepatic fibrosis improvement in HCV: What’s the link?

According to the results of a prospective cohort study, 57% of patients with hepatitis C virus (HCV) infection who achieved sustained virologic response (SVR) showed no improvement in hepatic fibrosis.…

Norah Terrault, MPH, MD: Managing DAA Failures When Treating Hepatitis C Virus Infections

Patient nonadherence to treatment is an ongoing issue that physicians from all specialties face. It is particularly prevalent among patients who are infected with hepatitis C virus. Gaps in treatment…

NIH scientists illuminate causes of hepatitis B virus-associated acute liver failure

National Institutes of Health scientists and their collaborators found that hepatitis B virus (HBV)-associated acute liver failure (ALF) — a rare condition that can turn fatal within days without liver…

AbbVie’s MAVYRET shows high virologic cure rates in treatment-naïve hepatitis C patients with compensated cirrhosis

-- EXPEDITION-8 is the first Phase 3b study evaluating 8 weeks of MAVYRET™ (glecaprevir/pibrentasvir) in treatment-naïve chronic hepatitis C virus (HCV)-infected patients with compensated cirrhosis across all major genotypes (GT1-6)…

Sofosbuvir/ledipasvir cures most young children with hepatitis C

Almost all young children ages 3 to 6 years with chronic hepatitis C achieved sustained virological response after 12 weeks of treatment using sofosbuvir/ledipasvir oral granules, according to findings presented…

Do patients with chronic liver disease face higher DILI risk?

Research suggests a link of which drug developers should be aware, expert says SAN FRANCISCO -- Individuals with certain types of chronic liver disease may be particularly susceptible to drug-induced…

MPP signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir

Important collaboration will ensure affordable hepatitis C treatment options in low- and middle-income countries. San Francisco, 12 November 2018 – The Medicines Patent Pool (MPP) has today announced a new,…

Hepatitis C medications effective in people who inject drugs

SAN FRANCISCO — People who inject drugs can adhere to medication regimens well enough to be cured of hepatitis C, results from the ANCHOR trial show. The finding refutes the argument…

Hepatitis C is detectable in rectal and nasal fluid

High levels of hepatitis C virus can be found in the rectal and nasal fluids of people with high hepatitis C viral loads even when blood is not present, Austrian…